Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Calogero Vetro

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Annals of Hematology|April 12, 2024
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life studySalvatore Leotta, Uros Markovic, Andrea Duminuco, et al.
Annals of Hematology|February 8, 2018
Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL)Roberta Di Blasi, Chiara Cattaneo, Russell E Lewis, et al.
Blood|August 3, 2021
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AMLMaria Paola Martelli, Roberta Rossi, Alessandra Venanzi, et al.
The Lancet. Haematology|September 23, 2024
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trialDomenico Russo, Nicola Polverelli, Simona Bernardi, et al.
Cancer|August 21, 2025
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experienceRoberto Cairoli, Lorenzo Del Castello, Silvia Imbergamo, et al.
American Journal of Hematology|January 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating AgentsGiovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
Cancer|January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemiaElisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
American Journal of Hematology|November 22, 2025
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 PatientsMatteo Molica, Gema Miralles, Richard Dillon, et al.
Blood Advances|December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Blood Advances|February 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Annals of Hematology|April 12, 2024
Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life studySalvatore Leotta, Uros Markovic, Andrea Duminuco, et al.
Annals of Hematology|February 8, 2018
Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL)Roberta Di Blasi, Chiara Cattaneo, Russell E Lewis, et al.
Blood|August 3, 2021
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AMLMaria Paola Martelli, Roberta Rossi, Alessandra Venanzi, et al.
The Lancet. Haematology|September 23, 2024
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trialDomenico Russo, Nicola Polverelli, Simona Bernardi, et al.
Cancer|August 21, 2025
Gilteritinib in FLT3-mutated acute myeloid leukemia: A real-world Italian experienceRoberto Cairoli, Lorenzo Del Castello, Silvia Imbergamo, et al.
American Journal of Hematology|January 20, 2025
Impact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating AgentsGiovanni Marconi, Elisabetta Petracci, Giuseppe Lanzarone, et al.
Cancer|January 24, 2023
AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemiaElisabetta Todisco, Cristina Papayannidis, Nicola Fracchiolla, et al.
American Journal of Hematology|November 22, 2025
Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 PatientsMatteo Molica, Gema Miralles, Richard Dillon, et al.
Blood Advances|December 5, 2025
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Blood Advances|February 24, 2026
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351Raffaele Palmieri, Fabio Guolo, Luana Fianchi, et al.
Pageof 7